Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma
about
GSK3A is redundant with GSK3B in modulating drug resistance and chemotherapy-induced necroptosisRole of Epigenetics in Uveal MelanomaIdentifying the structure-activity relationship of leelamine necessary for inhibiting intracellular cholesterol transport.6-Bromoindirubin-3'oxime (BIO) decreases proliferation and migration of canine melanoma cell lines.The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction.Clinico-Pathological Association of Delineated miRNAs in Uveal Melanoma with Monosomy 3/Disomy 3 Chromosomal Aberrations.Role of glycogen synthase kinase-3β inhibitor AZD1080 in ovarian cancer.The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.Effects of the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3'-oxime upon ovarian cancer cells.Targeting protein kinase-b3 (akt3) signaling in melanoma.New methods to control neuroblastoma growth.Moving synergistically acting drug combinations to the clinic by comparing sequential versus simultaneous drug administrations.Metastasis suppressor 1 (MTSS1) expression is associated with reduced in-vivo metastasis and enhanced patient survival in lung adenocarcinoma.Identification of WEE1 as a target to make AKT inhibition more effective in melanoma.Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatment.
P2860
Q28540209-4A9EA8FF-DF53-4D41-9601-BD61F601CC7FQ33703270-01DF6A0D-B1C5-4755-9B8F-1E5F63F81F7AQ33709666-E0661CE0-F018-44C3-8F51-5BCE4F8F30AEQ35033796-CBA67B50-6ED1-4861-B2CC-9AAC62E81F27Q35856555-7ECBABDF-F108-400E-B1EA-07DB4AF49573Q35904981-C6CD131A-856B-442E-9F85-03713CD79620Q36729132-B416454F-0E1C-4E71-9F9A-5AED5D4D2F51Q38695102-2F1BD955-C904-4A56-9BB7-32842E975341Q38822772-5987EDE2-3CFC-44D8-9C9F-756BCD8E1AA3Q39074281-496AEB1D-863A-4DD1-8BD0-C9AA8910A18DQ39741776-AC0C43AB-C0C8-4165-A6EB-CCC8BC1DEAA6Q47292160-8D74965E-D5AB-450B-BA2C-24A1A2751121Q47346343-215739E6-FFD0-4DD7-9847-FA9FF5D691E7Q48155250-10FA2B6E-ABD8-4140-BB5A-A747F39CAA28Q50113740-B9759CC9-1E57-4C93-B2EE-57372E667FAD
P2860
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma
@ast
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma
@en
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma.
@nl
type
label
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma
@ast
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma
@en
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma.
@nl
prefLabel
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma
@ast
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma
@en
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma.
@nl
P2860
P356
P1476
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma
@en
P2093
Raghavendra Gowda
SubbaRao V Madhunapantula
P2860
P304
P356
10.1111/PCMR.12156
P577
2013-09-19T00:00:00Z